Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Mannequinon Apr 11, 2024 3:13pm
179 Views
Post# 35984000

Get a deal done

Get a deal done

My two cents. Worth at least double that.

I believe we are on much better ground. However I do have some concerns which will not be resolved until a deal is done.

This team has failed to add a complimentary new product to sell with their in-house sales team (not sure I understand how/why), have not found a partner for NASH (somewhat understandable), have yet to find a partner thus far with oncology (also somewhat understandable) and failed to cut costs quickly enough which caused a massive drop in share price. We have witnesses and experienced a significant drop with a lack of protecting shareholder value by doing a financing that was timed to destroy long time shareholder equity.

We now need to give Marathon the boot, but in the best world that is done by cash from a partnership in oncology. 

We have a very VERY highly paid CEO who has certainly not delivered. We have a CFO that was unable to realize that Marathon was going to put the screws to them, and did. And, a CFO who did not take action soon enough.  We have a BOD that until recently had no one capable of standing up, and now we only have one BOD member who I believe is potentially someone who can help.  However, we know Zwick is likely from Soleus, and we have another from our last investor. They may be only looking out for those two parties.  Who is looking out for us?

For the love of God, prove you can execute and deliver on a new product addition or a new partner.

<< Previous
Bullboard Posts
Next >>